+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

19 February 2020
Pharma

Visiongain has launched a new pharma report Cell Therapy Technologies Market Report: Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research Institutes.

Cell therapy technology is one of the fastest growing markets and is an ever-changing landscape. It represents the umbrella of recent advancement in the field of gene therapy, drug delivery, cancer vaccines, various application of stem cells, regenerative medicine, and tissue engineering. Higher government investments for cell-based research, availability of advanced cell therapy technologies and growing demand of cell therapies are expected to further propel the market growth.

The lead analyst of the report commented "Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade. While the global market will experience significant growth, the Asia Pacific region is expected to be the fastest growing submarket, primarily due to the presence of large numbers of Clinical Research Organisations (CROs) in the region. The main restraints of growth in this market are the complex regulations and ethical issues governing cell therapy research, which have limited the number of clinical trials approved. However, this is being countered by innovative technologies from manufacturers, which are increasingly solving the challenges of scalability and safety associated with cell therapies."

Leading companies featured in the report include Thermo Fisher Scientific, Inc., Merck KGaA, Terumo Bct, Inc., Lonza Group, GE Healthcare and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

Read

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

Read

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

Read

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever